To be able to develop immuno-oncology pills, Sanofi collaborated Evotec and Apeiron.
Due to increase of death cases caused by cancer, Sanofi aventis partners Evotec AG and Apeiron Biologics AG in Vienna Austria. The partners with two biotech companies aims to develop cancer treatment, this turns the body’s own immune cells fight against tumors. Collaborative effort to create drug to prevent cancer from spreading all around the body.
Cancer mainly refers to group of diseases. This involves abnormal cell growth with the potential to invade or spread to other parts of the body and kills a certain person with no early treatment. Reasons for Sanofi fund two years of research at biotech companies to fight such killer disease.
Sanofi aventis, a French multinational pharmaceutical company founded in 1973 and headquartered in Paris, France. The company engages not only on research and development as well as marketing and manufacturing pharmaceutical drugs. It covers major therapeutic areas, this includes cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines.
Victoria Richon, Vice President and Head of Research of Cancer Sanofi, “Immuno-Oncology has become a particularly promising area for the creation of potentially curative treatment options for many cancer patients,” said in a statement. “Our partnership with Evotec and Apeiron Biologics experts will help us take the next step towards realizing the full value of these innovative treatments.”
Sanofi aventis also announced its desire, partnership with Evotec last week aiming to develop stem cell-based treatments for diabetes and working closely with its long-time partner Regeneron Pharmaceuticals in the area of cancer immunotherapy.
The Evotec AG is a drug discovery alliance and development partnership company. It focused on progressing product approaches with pharmaceutical and biotechnology companies as well. Hundreds of its scientists works in key therapeutic areas, such as neurology like Alzheimer disease and others, diabetes, inflammation and infectious diseases.
The company spent billions in 2010 mergers to strengthen its consumer healthcare and generics platforms especially in emerging markets, when Chris Viebacher was hired as CEO, 2008. Company faces growth of the consumer healthcare segment and experience decreased of its earning in the third quarter when generic competitors ate into profits of its Eloxatin cancer treatment, October 2012. IMAGE/Bloomberg.com